Dalertuximab, a humanized monoclonal antibody targeting CD38, has demonstrated anti-tumor activity and has been approved for the treatment of multiple myeloma by mediating antibody-dependent cellular cytotoxicity (ADCC) and modulating the tumor immune microenvironment (14, 44). This evidence concerns the gene CD38 and neoplasm.